Mr. Eric So reports

HELUS PHARMA PARTNERS WITH TARA MIND TO ADVANCE VETERAN MENTAL HEALTH

Cybin Inc. (doing business as Helus Pharma) has formed a collaboration with TARA Mind, which works with Veterans Exploring Treatment Solutions (VETS) to support clinical trial recruitment for its Paradigm HLP003 phase 3 program for major depressive disorder (MDD), while expanding mental health awareness and access within the veteran community.

This partnership directly aligns with President Trump's April 18, 2026, Executive Order, "Accelerating Medical Treatments for Serious Mental Illness," which emphasizes expanding clinical research participation and advancing innovative treatment approaches for populations, including veterans, who face disproportionately high rates of depression, PTSD and suicide.

"Veterans face significant mental health challenges, and expanding awareness and access to clinical research opportunities is an important step toward improving outcomes," said Eric So, interim chief executive officer of Helus Pharma. "TARA Mind and VETS bring deep experience working with veteran communities. These collaborations will support recruitment efforts for our FDA breakthrough therapy-designated HLP003 program while aligning with the broader priorities highlighted in the recent Executive Order to expand research participation and advance innovative treatments for serious mental illness."

TARA Mind and VETS will leverage their deep networks to facilitate veteran engagement and support recruitment for the continuing Paradigm HLP003 phase 3 program, part of Helus Pharma's broader pipeline of NSAs addressing unmet needs in mental health.

"The recent Executive Order reinforces the importance of expanding awareness around mental health challenges affecting veterans and ensuring communities have access to information about emerging research," said Marcus Capone, chairman and co-founder of TARA Mind. "Partnerships like this help strengthen outreach efforts, connect veterans to cutting-edge clinical opportunities and ensure veterans have the latest resources that support their mental health."

These collaborations reflect Helus Pharma's commitment to patient-centric innovation and responsible clinical development in one of the most pressing areas of veteran health care.

About Cybin Inc. (Helus Pharma)

Helus Pharma, the commercial operating name of Cybin, is a clinical stage pharmaceutical company committed to helping minds heal by developing proprietary NSAs -- novel serotonergic agonists: synthetic molecules designed to activate serotonin pathways that are believed to promote neuroplasticity. The company's proprietary NSAs are intended to address the large unmet need for people who suffer from depression, anxiety and other mental health conditions.

With class-leading data, Helus Pharma aims to improve the treatment landscape through the introduction of NSAs that aim to provide durable improvements in mental health. Helus Pharma is currently developing HLP003, a proprietary NSA, in phase 3 clinical development for the adjunctive treatment of major depressive disorder that has received breakthrough therapy designation from the U.S. Food and Drug Administration and HLP004, also a proprietary NSA in phase 2 for generalized anxiety disorder. Additionally, Helus Pharma has an extensive research portfolio of investigational NSAs.

The company operates in Canada, the United States, the United Kingdom and Ireland.

About TARA Mind

Founded in 2022 by Marcus Capone, a veteran Navy SEAL turned entrepreneur after experiencing the life-changing benefits of psychedelic-assisted therapy, TARA Mind is advancing its mission to provide safe, effective and affordable access to life-changing mental health therapies through its collaborative care platform and structured real world evidence data set. TARA Mind has developed a first-of-its-kind mental health collaborative care platform, recognized for being clinician guided, data driven and evidence based, to help the millions of individuals struggling with mental health disorders that have not been clinically responsive to traditional mental health therapies.